Keyword Analysis & Research: asparaginase erwinia chrysanthemi recombinant


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
asparaginase erwinia chrysanthemi recombinant1.070.792356145
asparaginase1.90.477807912
erwinia0.940.5878597
chrysanthemi0.570.451932412
recombinant1.6170209711

Keyword Research: People who searched asparaginase erwinia chrysanthemi recombinant also searched

Keyword CPC PCC Volume Score
asparaginase erwinia chrysanthemi recombinant1.550.2405299

Search Results related to asparaginase erwinia chrysanthemi recombinant on Search Engine

  • FDA approves asparaginase erwinia chrysanthemi (recombinant…

    fda.gov

    https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asparaginase-erwinia-chrysanthemi-recombinant-leukemia-and-lymphoma

    WebOn June 30, 2021, the Food and Drug Administration approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as a component of a multi-agent...

    DA: 25 PA: 2 MOZ Rank: 50

  • FDA Approves Rylaze for Childhood ALL - NCI - National Cancer Institute

    cancer.gov

    https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-rylaze-asparaginase-childhood-leukemia

    WebJul 29, 2021 · On June 30, FDA approved a new form of asparaginase, erwinia chrysanthemi (recombinant)-rywn (Rylaze), which was developed to address the ongoing shortages of Erwinia asparaginase. Rylaze was approved as part of a treatment regimen for children and adults with ALL or lymphoblastic lymphoma (LBL), a rare but aggressive …

    DA: 95 PA: 25 MOZ Rank: 22

  • FDA approves a new dosing regimen for asparaginase erwinia chrysanthemi …

    fda.gov

    https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-new-dosing-regimen-asparaginase-erwinia-chrysanthemi-recombinant

    WebOn November 18, 2022, the Food and Drug Administration approved a new Monday-Wednesday-Friday dosing regimen for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze, Jazz...

    DA: 65 PA: 74 MOZ Rank: 98

  • Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn - NCI

    cancer.gov

    https://www.cancer.gov/about-cancer/treatment/drugs/asparaginase-erwinia-chrysanthemi-recombinant

    WebAsparaginase erwinia chrysanthemi (recombinant)-rywn is used in patients who can no longer take asparaginase made from E. coli. It is a recombinant form of asparaginase made from the bacterium Erwinia chrysanthemi. This drug is …

    DA: 65 PA: 74 MOZ Rank: 45

  • Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze

    prnewswire.com

    https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-us-fda-approval-of-rylaze-asparaginase-erwinia-chrysanthemi-recombinant-rywn-for-the-treatment-of-acute-lymphoblastic-leukemia-or-lymphoblastic-lymphoma-301323782.html

    WebJul 1, 2021 · DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze ™ (asparaginase erwinia...

    DA: 16 PA: 48 MOZ Rank: 9


  • Recombinant Erwinia asparaginase (JZP458) in acute …

    ashpublications.org

    https://ashpublications.org/blood/article/141/7/704/486644/Recombinant-Erwinia-asparaginase-JZP458-in-acute

    WebFeb 16, 2023 · Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study | Blood | American Society of Hematology. CLINICAL TRIALS AND OBSERVATIONS | February 16, 2023. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase …

    DA: 32 PA: 29 MOZ Rank: 63

  • FDA Approves Component of Treatment Regimen for Most …

    fda.gov

    https://www.fda.gov/news-events/press-announcements/fda-approves-component-treatment-regimen-most-common-childhood-cancer

    WebToday, the U.S. Food and Drug Administration approved Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component of a chemotherapy regimen to treat acute lymphoblastic...

    DA: 72 PA: 61 MOZ Rank: 28

  • Asparaginase Erwinia Chrysanthemi (recombinant)-rywn …

    medlineplus.gov

    https://medlineplus.gov/druginfo/meds/a621042.html

    WebAsparaginase erwinia chrysanthemi (recombinant)-rywn is an enzyme that interferes with natural substances necessary for cancer cell growth. It works by killing or stopping the growth of cancer cells. How should this medicine be used?

    DA: 70 PA: 52 MOZ Rank: 67

  • Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn for …

    ascopost.com

    https://ascopost.com/issues/august-10-2021/asparaginase-erwinia-chrysanthemi-recombinant-rywn-for-acute-lymphoblastic-leukemia-and-lymphoblastic-lymphoma/

    WebJun 30, 2021 · Asparaginase erwinia chrysanthemi (recombinant) was approved as a component of a multiagent chemotherapeutic regimen for treatment of ALL and lymphoblastic lymphoma in adult and pediatric patients 1 month or older who have developed hypersensitivity to E coli –derived asparaginase.

    DA: 100 PA: 18 MOZ Rank: 88

  • Recombinant Erwinia asparaginase (JZP458) in acute ... - PubMed

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/36108304/

    WebFeb 16, 2023 · AALL1931, a phase 2/3 study conducted in collaboration with the Children's Oncology Group, investigated the efficacy and safety of JZP458 (asparaginase erwinia chrysanthemi [recombinant]-rywn), a recombinant Erwinia asparaginase derived from a novel expression platform, in patients with acute lymphoblastic leukemia/lymphoblastic …

    DA: 38 PA: 80 MOZ Rank: 72